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Iron-overload cardiomyopathy is a rare condition that is
associated with ventricular arrhythmias. The appropriate
management of patients presenting with iron-overload car-
diomyopathy and ventricular tachycardia often has to be
individualized. We present a case of a young man presenting
with life-threatening ventricular tachycardia as a result of
iron-overload cardiomyopathy and discuss the management
of the case.Case report
A 25-year-old male patient presented with acute onset of
chest pain and dizziness. He was found to have hemody-
namically compromising refractory ventricular tachycardia
(Figure 1), which necessitated more than 10 episodes of
cardioversion with intravenous lignocaine before the tachyar-
rhythmia ceased.
The patient has a history of beta thalassemia major that
has required regular blood transfusions as well as concom-
itant self-administered subcutaneous chelation therapy with
deferoxamine with deferiprone for the past 5 years. How-
ever, he had been noncompliant with his chelation therapy.
Serum ferritin concentrations were 3083 µg/L (normal
range: 24–336 µg/L). The cardiac magnetic resonance
images showed the left ventricle (LV) to be mildly dilated
but with normal ejection fraction. The LV myocardium
appeared diffusely dark in the steady-state free precession
(SSFP) sequences (Figure 2) with a T2* time of 3.2 milli-
seconds (normal: 420 milliseconds), which is consistent
with severe myocardial iron deposition. This phenomenon
was at a level that placed him at high risk for cardiac
decompensation and arrhythmias. Dark signal intensity of
the liver was also noted, with a T2* value of 1.4 milli-
seconds, which is consistent with severe liver iron loading
(Figure 2). The right ventricle systolic function andKEYWORDS Iron-overload cardiomyopathy; Implantable cardioverter-
deﬁbrillator; Ventricular tachycardia
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akinetic, or dyskinetic segments to suggest a right ventricular
cardiomyopathy.
Aggressive intravenous chelation therapy was started. In
view of the refractory nature of the ventricular tachycardia,
the option of implantable cardioverter-deﬁbrillator (ICD)
was explored and accepted, and a device was subsequently
implanted, after which the patient was discharged well.
Three months post discharge, while undergoing iron chela-
tion therapy, ICD interrogation revealed that he had suffered
several episodes of recurrent ventricular tachycardia, which
were successfully cardioverted by the ICD. Serum ferritin
concentrations had by then come down to 1247 µg/L. One
year post ICD implantation, a repeat cardiac magnetic
resonance imaging study was performed. The repeat study
showed persistent severe myocardial iron loading with a
myocardial T2* value of 3.6 milliseconds. His liver iron
loading, however, had signiﬁcantly improved to 3.6 milli-
seconds. Serum ferritin levels had come down further, to 692
µg/L.Discussion
The incidence of iron-overload cardiomyopathy in thalasse-
mia major ranges from 11.4% to 15.1%.1,2 Signiﬁcant
myocardial iron loading is associated with an increased risk
of developing cardiac arrhythmias, yet review of the
literature suggests that ventricular arrhythmias account for
only a small proportion of all arrhythmias in this condition.3
Current guidelines4 do not specify the use of an ICD for
the primary or secondary prevention of sudden cardiac death
in a potentially reversible condition such as iron-overload
cardiomyopathy. Iron chelation therapy signiﬁcantly reduces
myocardial iron content and reverses iron-overload cardio-
myopathy.5 This phenomenon suggests that an ICD insertion
may not be immediately indicated or required in secondary
prevention. The primary objective of management in secon-
dary prevention of malignant arrhythmias in such cases may
therefore potentially be limited to the prescription of antiar-
rhythmic medications to prevent recurrent episodes in the
short to medium term with concurrent intensive iron chela-
tion to achieve rapid myocardial iron off-loading.
Published data, however, imply that iron clearance from
myocardium is very slow, with a half-life of 13–14 months
(4 times that of liver clearance), even with intravenouspen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Iron-overload cardiomyopathy is an uncommon
cause of cardiomyopathy that is associated with
increased risk of cardiac arrhythmias.
 The main aim of iron chelation therapy is to
decrease the amount of iron deposition in the
myocardium as well as other organs, such as
the liver.
 The effectiveness of chelation therapy to reduce
the incidence of arrhythmias associated with iron-
overload cardiomyopathy is presently unclear.
 The use of an implantable cardioverter-deﬁbrillator
may be considered for patients presenting with
ventricular tachyarrhythmias.
99Foo and Joseph Iron Man Ventricular Tachycardiachelation.6 Thus, a management dilemma regarding the exact
timing of ICD implantation, if any, seems to arise. One
would struggle with the beneﬁt of preventing sudden cardiac
death afforded by an early ICD implantation versus waiting
for signiﬁcant myocardial iron off-loading to take place, to
reduce the risk of further arrhythmia recurrence. In this patient,
3 months post ICD insertion, despite ferritin levels decreasing
to one-third of the value observed on the ﬁrst presentation,
parallel ICD interrogation demonstrated the recurrence of
sustained ventricular tachycardia, which was successfully
terminated with cardioversion. This occurrence could have
been potentially fatal if the patient had not had an ICD
implanted during the index hospitalization.
Myocardial iron loading may be present independent of a
matched degree of hepatic hemosiderosis or, conversely,
may be spared despite signiﬁcant loading of other organs.7
Serum iron and ferritin content or estimation of liver iron
content by biopsy has therefore limited ability to predict
myocardial iron content. Monitoring myocardial iron overloadFigure 1 Monomorphic ventriculaduring iron chelation therapy is not feasible by repeated
myocardial biopsy, because of the spatial and temporal
heterogeneity of iron distribution and the inherent risk of
complications with this procedure.
Magnetic resonance imaging T2* is now widely used for
the quantiﬁcation of myocardial iron. Data from studies
using myocardial biopsy have shown that cardiac T2*
relaxation times are in strong agreement with myocardial
iron content quantiﬁed by myocardial biopsy.8,9 Addition-
ally, serum ferritin concentrations also do not correlate with
myocardial T2* values.10
Magnetic resonance imaging T2* is an ideal noninvasive
tool for the monitoring of myocardial iron content as well as
LV function during iron chelation therapy. Longitudinal data
suggest that both myocardial T2* times and LV function
improve in parallel, in response to intensive chelation
therapy.6 It is uncertain whether the incidence and preva-
lence of arrhythmias resulting from iron load cardiomyop-
athy will decrease with the improvement in myocardial T2*
times or LV function. Studies have shown that 83% of
patients with iron-overload cardiomyopathy and arrhythmias
had myocardial T2* times of o20 milliseconds.3 The
threshold T2* value beyond which arrhythmias cease to be
a concern has yet to be determined, but it most likely
overlaps with normal values. A value above 20 milliseconds
is generally considered to be normal, and this value seems to
be a reasonable goal to work toward to signiﬁcantly reduce
the possibility of arrhythmia occurrence.
The paucity of clinical trials addressing the most appro-
priate management for ventricular arrhythmias in iron-overload
cardiomyopathy implies that the consideration for an ICD
implant must take an individualized approach. Iron-overload
cardiomyopathy patients who present with life-threatening
ventricular arrhythmias therefore may be suitable candidates
for ICD implantation for the prevention of sudden cardiac
death while they wait for appropriate iron chelation therapy to
take its ameliorating effect on arrhythmias, if any occur.r tachycardia on presentation.
Figure 2 Midsegment short-axis steady-state free precession (SSFP) view of A: the patient’s heart revealed that both the heart (dashed white arrow) and the
liver (bold white arrow) have low signal intensity compared with that of B: a normal control.
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